George G. Shapovalov
Villeneuve-d'ascq, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Targeting TRPV6/CXCR4 complexes prevents castration-resistant prostate cancer metastasis to the bone.
Journal: Signal transduction and targeted therapy
Published: April 08, 2025
Trpv6 channel targeting using monoclonal antibody induces prostate cancer cell apoptosis and tumor regression.
Journal: Cell death & disease
Published: November 20, 2023
Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 25, 2022
NALCN-mediated sodium influx confers metastatic prostate cancer cell invasiveness.
Journal: The EMBO journal
Published: July 23, 2022
Allosteric cross-talk between the hydrophobic cleft and the BH4 domain of Bcl-2 in control of inositol 1,4,5-trisphosphate receptor activity.
Journal: Exploration of targeted anti-tumor therapy
Published: November 02, 2021
Store operated calcium channels in cancer progression.
Journal: International review of cell and molecular biology
Published: August 16, 2021
TRPC3 shapes the ER-mitochondria Ca2+ transfer characterizing tumour-promoting senescence.
Journal: Nature communications
Published: September 03, 2019
4TM-TRPM8 channels are new gatekeepers of the ER-mitochondria Ca2+ transfer.
Journal: Biochimica et biophysica acta. Molecular cell research
Published: October 05, 2017
Metabolic Disorders and Cancer: Store-Operated Ca2+ Entry in Cancer: Focus on IP3R-Mediated Ca2+ Release from Intracellular Stores and Its Role in Migration and Invasion.
Journal: Advances in experimental medicine and biology
Published: September 14, 2017
Organelle membrane derived patches: reshaping classical methods for new targets.
Journal: Scientific reports
Published: October 21, 2016
The trans-membrane domain of Bcl-2α, but not its hydrophobic cleft, is a critical determinant for efficient IP3 receptor inhibition.
Journal: Oncotarget
Published: March 03, 2016
Last Updated: 09/26/2026